Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively ...

Basically, ERAS targets RAS/MAPK pathways, which helps prevent cancerous ... The first one is for KRAS-mutated solid tumors, and the latter is for EGFR and RAS/MAPK solid tumors.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Ezrin loss reduces downstream MAPK and Akt signaling ... findings are consistent with past literature demonstrating Ezrin's role in the EGFR and mTORC1 signaling pathways. They used several cell lines ...

The drugs involved in this review are MAPK pathway inhibitors, poly (ADP-ribose ... including epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), fibroblast ...

EGFR functions by activating many intracellular signaling pathways following binding of various ligands ... the resultant activation of the intermediate proteins PI3K, mTORC1 and MAPK drive peripheral ...

Despite the established links between inflammation and cancer development, the effects of inflammatory signaling on cancer ...

"With the addition of VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, we are well-positioned to further establish our leadership in targeting RAS/MAPK pathway-driven cancers ...

Here we report an activity-dependent stabilization of the MAP kinase (MAPK) pathway, prominent in hippocampal dendrites. The longevity of the signal in these dendrites was increased to hours when ...

This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

Yeah, so the EGFR mutation lung cancer field has really expanded. We usually think about EGFR as the classical mutation, deletion 19 and 858R mutation. But in the last, I will say, five to 10 ...